AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Tango Therapeutics, Inc.
Video analysis: TNGX
All videosNo video analysis for this stock yet. Request one from our team.
News: TNGX
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
Algert Global LLC Grows Position in Tango Therapeutics, Inc. $TNGX
Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,570 shares of the company's stock after purchasing an additional 125,930 shares during the
Tango Therapeutics, Inc. $TNGX Shares Sold by Bank of America Corp DE
Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 327,144 shares of the company's stock after selling 150,918 shares during the quarter. Bank of
ADAR1 Capital Management LLC Invests $2.40 Million in Tango Therapeutics, Inc. $TNGX
ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,761 shares of the company's stock, valued at approximately $2,400,000. A number of other institutional investors have also made
Tango Therapeutics: Promising Early Data, But A Long Road Ahead
Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned front-line Phase 3 trial could substantially expand the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
